Type 1 Diabetes TrialNet: a multifaceted approach to bringing disease-modifying therapy toclinical use in type 1 diabetes

Polly J. Bingley, Diane K. Wherrett, Ann Shultz, Lisa E. Rafkin, Mark A. Atkinson, Carla J. Greenbaum*

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)

18 Citations (Scopus)

Abstract

What will it take to bring disease-modifying therapy to clinical use in type 1 diabetes? Coordinated efforts of investigators involved in discovery, translational, and clinical research operating in partnership with funders and industry and in sync with regulatory agencies are needed. This Perspective describes one such effort, Type 1 Diabetes TrialNet, a National Institutes of Health-funded and JDRFsupported international clinical trials network that emerged from the Diabetes Prevention Trial-Type 1 (DPT-1). Through longitudinal natural history studies, as well as trials before and after clinical onset of disease combined with mechanistic and ancillary investigations to enhance scientific understanDing and translation to clinical use, TrialNet is working to bring disease-modifying therapies to individuals with type 1 diabetes. Moreover, TrialNet uses its expertise and experience in clinical studies to increase efficiencies in the conduct of trials and to reduce the burden of participation on individuals and families. Herein, we highlight key contributions made by TrialNet toward a revised understanDing of the natural history of disease and approaches to alter disease course and outline the consortium's plans for the future.

Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalDiabetes Care
Volume41
Issue number4
Early online date12 Mar 2018
DOIs
Publication statusPublished - 12 Mar 2018

Fingerprint Dive into the research topics of 'Type 1 Diabetes TrialNet: a multifaceted approach to bringing disease-modifying therapy toclinical use in type 1 diabetes'. Together they form a unique fingerprint.

Cite this